Clinical trial · no report yet · Phase 1
inMMyCAR
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- NCT07075185 ↗
- Recruiting
- Kelonia Therapeutics, Inc.
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 29 | |
| YouTube | 8 | |
| Podcasts | 1 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Multiple Myeloma in Relapse; Myeloma Multiple; Multiple Myeloma Progression; Neoplasms by Histologic Type; Neoplasm; Hemostatic Disorders; Vascular Disorder; Paraproteinemias; Blood Protein Disorders; Hematologic Disease and Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Disease; Gene Therapy
- Interventions
- KLN-1010
- Arms
- KLN-1010 · Experimental
- Enrollment
- 70 (estimated)
- Primary outcomes
- Incidence and severity of treatment-emergent adverse events (TEAEs), including dose-limiting toxicities (DLTs), and/or establish the recommended Phase 2 Dose
- Sponsor
- Kelonia Therapeutics, Inc.
- Start
- Jul 16, 2025
- Primary completion
- Mar 2027 (estimated)
- Results posted
- No
- Registry record
- NCT07075185 · updated Aug 28, 2026